Recent advances in cannabinoid receptor agonists and antagonists

Bibliography

• DEVANE WA, DYSARZ FA, JOHNSON MR, MELVIN LS,HOWLETT AC: Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol (1988) 34:605–613.
   PubMed Web of Science ®Google Scholar
• MUNRO S, THOMAS KL, ABU-SHAAR M: Molecularcharacterization of a peripheral receptor for cannabi-noids. Nature (1993) 365:61–65.
   PubMed Web of Science ®Google Scholar
• DEVANE WA, HANUS L, BREUER A et al.: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 258:1946–1949.
   PubMed Web of Science ®Google Scholar
• MECHOULAM R, BEN-SHABAT S, HANUS L et al.: Identifi-cation of endogenous 2-monoglyceride present in canine gut that binds to cannabinoid receptors. Biochem. Pharmacol. (1995) 50:83–90.
   PubMed Web of Science ®Google Scholar
• BAKER D, PRYCE G, CROXFORD JL et al: Cannabinoidscontrol spasticity and tremor in a multiple sclerosis model. Nature (2000) 404:84–87.
   PubMed Web of Science ®Google Scholar
• FUENTES JA, RUIZ-GAYO M, MANZANARES J et al:Cannabinoids as potential new analgesics. Life ScL (1999) 65:675–685.
   PubMed Web of Science ®Google Scholar
• SONG ZH, SLOWEY CA: Involvement of cannabinoidreceptors in the intraocular pressure-lowering effects of WIN55212-2. J. Pharmacol Exp. Ther. (2000) 292:136–139.
   PubMed Web of Science ®Google Scholar
• HILLARD CJ: Endocannabinoids and vascular function.J. Pharmacol Exp. Ther. (2000) 294:27–32.
   PubMed Web of Science ®Google Scholar
• GALVE-ROPERH I, SANCHEZ C, CORTES ML et al.: Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nature Med. (2000) 6:313.
   PubMed Web of Science ®Google Scholar
• BARTH F: Cannabinoid receptor agonists and antago-nists. Exp. Opin. Ther. Patents (1998) 8:301–313.
   Web of Science ®Google Scholar
• XIANG J-N, LEE JC: Pharmacology of cannabinoid recep to t agonists and antagonists. Ann. Rep. Med. Chem. (1999) 34:199–208.
   Google Scholar
• BARTH F, RINALDI-CARMONA M: The development of cannabinoid antagonists. Curr. Med. Chem. (1999) 6:745–755.
   PubMed Web of Science ®Google Scholar
• PIOMELLI D, GIUFFRIDA A, CALIGNANO A, RODRIGUEZDE FONSECA F: The endocannabinoid system as a target for therapeutic drugs. TiPS (2000) 21:218–224.
   PubMed Web of Science ®Google Scholar
• MECHOULAM R, FRIDE E, DI MARZO V: Review: endocannabinoids. Eur. j Pharmacol (1998) 359:1–18.
   PubMed Web of Science ®Google Scholar
• MARTIN BR, MECHOULAM R, RAZDAN RK: Discovery and characterization of endogenous cannabinoids. Life ScL (1999) 65:573–595.
   PubMed Web of Science ®Google Scholar
• HILLARD CJ, MANNA S, GREENBERG MJ et al: Synthesisand characterization of potent and selective agonists of the neuronal cannabinoid receptor (CBI). J. Pharmacol. Exp. Ther. (1999) 289:1427–1433.
   PubMed Web of Science ®Google Scholar
• SMART D, JERMAN JC: Anandamide: an endogenousactivator of the vanilloid receptor. TiPS (2000) 21:134.
   PubMed Web of Science ®Google Scholar
• KHANOLKAR AD, MAKRIYANNIS A: Structure-activityrelationships of anandamide, an endogenous cannabi-noid ligand. Life ScL (1999) 65:607–616.
   PubMed Web of Science ®Google Scholar
• CRAVATT BF, GIANG DK, MAYFIELD SP et al: Molecularcharacterisation of an enzyme that degrades neuromodulatory fatty acid amides. Nature (London) (1996) 384:83–87.
   PubMed Web of Science ®Google Scholar
• BELTRAMO M, STELLAN N, CALIGNANO A et al.: Functional role of high affinity anadamide transport as revealed by selective inhibition. Science (1997) 277:1094–1097.
   PubMed Web of Science ®Google Scholar
• LIN S, KHANOLKAR AD, FAN P et al: Novel analogues ofarachidonylethanolamide (anandamide): affinities for the CBI. and CB2 cannabinoid receptors and metabolic stability. J Med. Chem. (1998) 41:5353–5361.
   Google Scholar
• NG EW, AUNG MM, ABOOD ME, MARTIN BR, RAZDAN RK: Unique analogues of anandamide: arachidonyl ethers and carbamates and norarachidonyl carbamates and ureas. J. Med. Chem. (1999) 42:1975–1981.
   PubMedGoogle Scholar
• BARNETT-NORRIS J, GUARNIERI F, HURST DP, REGGIO PH: Exploration of biologically relevant conforma-tions of anandamide: 2-arachidonylglycerol and their analogues using conformational memories. J Med. Chem. (1998) 41:4861–4872.
   PubMed Web of Science ®Google Scholar
• TONG W, COLLANTES ER, WELSH WJ, BERGLUND BA, HOWLETT AC: Derivation of a pharmacophore model for anandamide using constrained conformational searching and comparative molecular field analysis. J Med. Chem. (1998) 41:4207–4215.
   PubMed Web of Science ®Google Scholar
• MECHOULAM R, HANUS L, FRIDE E: Towards cannabi-noid drugs-revisited. Prog. Med. Chem. (1998) 35:199–242.
   PubMedGoogle Scholar
• KEIMOWITZ AR, MARTIN BR, RAZDAN RK et al: QSAR analysis of A8-THC analogues: relationship of side-chain conformation to cannabinoid receptor affinity and pharmacological potency. J. Med. Chem. (2000) 43:59–70.
   PubMedGoogle Scholar
• KHANOLKAR AD, LU D, FAN P, TIAN X, MAKRIYANNIS A: Novel conformationally restricted tetracyclic analogs of A8-tetrahydrocannabinol. Bioorg. Med. Chem. Lett. (1999) 9:2119–2124.
   PubMedGoogle Scholar
• MARTIN BR, JEFFERSON R, WINCKLER R et al.: Manipula-tion of the tetrahydrocannabinol side chain delineates agonists, partial agonists and antagonists. J Pharmacol Exp. Ther. (1999) 290:1065–1079.
   PubMedGoogle Scholar
• CROCKER PJ, SAHA B, RYAN WJ et al: Development of agonists, partial agonists and antagonists in the A8-tetrahydrocannabinol series. Tetrahedron (1999) 55:13907–13926.
   Google Scholar
• BAEK SH, KANG KU, HAN DS, KIM HM: Synthesis andanalgesic activity of non-classical bicyclic cannabi-noid analogues. Pharm. Pharmacol Commun. (1999) 5:495–500.
   Google Scholar
• HANUS L, BREUER A, TCHILIBON S, SHILOAH S, GOLDEN-BERG D et al.: HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor. Proc. Natl. Acad. ScL USA (1999) 96:14228–14233.
   PubMed Web of Science ®Google Scholar
• DAJANI EZ, LARSEN KR, TAYLOR J et al.: 1 ',V-Dimethylheptyl-A-8-tetrahydrocannabino1-11-oic acid: a novel, orally effective cannabinoid with analgesic and anproperties. J.Pharmacol. Exp. Ther. (1999) 291:31–38.
   PubMed Web of Science ®Google Scholar
• PORTIER M, RINALDI-CARMONA M, PECCEU F et al.: SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist. J. Pharmacol. Exp. Ther. (1999) 288:582–589.
   PubMed Web of Science ®Google Scholar
• LAN R, LIU Q, FAN P et al.: Structure-activity relation-ships of pyrazole derivatives as cannabinoid receptor antagonists. J Med. Chem. (1999) 42 :769–776.
   PubMedGoogle Scholar
• THOMAS BF, GILLIAM AF, BURCH DF, ROCHE MJ, SELTZMAN HH: Comparative receptor binding analyses of cannabinoid agonists and antagonists. J Pharmacol. Exp. Ther. (1998) 285:285–292.
   PubMedGoogle Scholar
• KANYONYO M, GOVAERTS SJ, HERMANS E, POUPAERT JH, LAMBERT DM: 3-Alkyl-(5,5'-diphenyl)imidazolidine diones as new cannabinoid receptor ligands. Bioorg. Med. Chem. Lett. (1999) 9:2233–2236.
   PubMedGoogle Scholar
• HUFFMAN JW: Cannabimimetic indoles, pyrroles and indenes. Curr. Med. Chem. (1999) 6:705–720.
   PubMed Web of Science ®Google Scholar
• XIE X-Q, HAN X-W, CHEN J-Z, EISSENSTAT M, MAKRIY-ANNIS A: High-resolution NMR and computer modeling studies of the cannabimimetic aminoalky-lindole prototype WIN-55212-2. J. Med. Chem. (1999) 42:4021–4027.
   PubMedGoogle Scholar
• SONG ZH, SLOWEY CA, HURST DP, REGGIO PH: The difference between the CBI. and CB2 cannabinoid receptors at position 5.46 is crucial for the selectivity of WIN55212-2 for CB2. MoL PharmacoL (1999) 56:834–840.
   Google Scholar
• PERTVVEE RG: Cannabis and cannabinoids: pharma-cology and rationale for clinical use. Forsch. Komple-mentarmed. (1999) 3:12–15.
   Google Scholar